Loading stock data…
$19.84-0.44 (-2.17%)
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Assembly Biosciences, Inc. in the Healthcare sector is trading at $19.84 with a market capitalization of $459M. Wall Street consensus targets $52.00 (5 analysts), implying a +162.1% move over the next 12 months. The stock is currently near its 52-week low of $19.30, remaining 27.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $13.37M↑ | $8.21M↓ | $42.47M↑ | $10.79M↑ | $9.63M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.34M↑ | -$11.37M↓ | $19.80M↑ | -$10.88M↑ | -$11.09M |
| Net Income | -$3.86M↑ | -$9.08M↓ | $22.09M↑ | -$9.20M↑ | -$10.20M |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are i...